Clinical trial

Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer

NCT02530411

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Vandetanib Normalized identity: vandetanibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2015-04-01

PhasePHASE2

Conditions

Neoplasmsunresolved

Interventions

FulvestrantDRUG · verified · RxNorm: fulvestrant

VandetanibDRUG · verified · RxNorm: vandetanib

Sponsors & collaborators

Velindre NHS Trustlead sponsor

Cancer Research UKcollaborator

AstraZenecacollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02530411 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.